Lansoprazole

Quick links to important sections

Lansoprazole

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lansoprazole

Quick Facts: Lansoprazole

Property Description
Active ingredient Lansoprazol (INN)
Form Capsules (delayed-release), ODTs, IV Solution
Pharmacological class Proton Pump Inhibitor (PPI)
Origin Synthetic compound
Mechanism principle Acid pump blockade

What Type of Medicine is Lansoprazole?

Lansoprazole is a synthetic compound categorized as a Proton Pump Inhibitor (PPI), positioning it as a potent antiulcer agent used to manage excessive gastric acid production. Its primary function is to decrease the amount of acid made in the stomach. This classification highlights the drug's specialized action compared to older acid reducers. The active ingredient, Lansoprazol, is the basis for several recognized brand-name products globally, such as Prevacid and Zoton, underscoring its significant commercial presence.

Lansoprazole's Composition and Available Forms

Lansoprazol is formulated as a single ingredient product and chemically belongs to the substituted benzimidazole group. This compound functions as a prodrug, meaning it requires activation within the body's acidic environment. For patient use, it is supplied in various pharmaceutical preparations for both oral and intravenous administration, primarily including delayed-release capsules and orally disintegrating tablets (ODTs). Oral formulations are specifically designed to ensure the active ingredient remains intact during its passage through the stomach. This enteric protection is a distinguishing feature necessary for the Lansoprazol to be absorbed efficiently and transported to the stomach lining.

What is the General Purpose of Lansoprazole?

The general purpose of Lansoprazole is to provide sustained gastric acid secretion reduction to mitigate the damage and discomfort caused by high acid levels. Its key mechanism involves the irreversible inhibition of the final step of acid secretion within the parietal cells. This action ensures the stomach environment remains consistently less corrosive, thereby alleviating irritation and facilitating the natural healing of affected tissues. This therapeutic effect is clinically recognized for controlling hyperacidity.

What side effects are possible with Lansoprazole?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of Lansoprazole by frequency and the body system affected. These classifications ensure transparency regarding the documented risks associated with the medicine.

Frequency-Classified Adverse Reactions

Classification Examples of Reactions (SOC Group)
Common Diarrhea, headache, nausea, abdominal pain, increased liver enzymes (Hepatobiliary Disorders).
Uncommon Depression (Psychiatric), arthralgia (Musculoskeletal), bone fracture of the hip, wrist, or spine.
Rare Fever, confusion, interstitial nephritis (Renal), severe blood changes (Blood and Lymphatic).
Very Rare Agranulocytosis, severe cutaneous reactions (e.g., SJS, TEN).
Not Known Hypomagnesemia, hypocalcemia, Subacute Cutaneous Lupus Erythematosus (SCLE).

Documented Serious Adverse Reactions and Safety Constraints

The official labeling notes that rare, but serious, adverse reactions include Acute Tubulointerstitial Nephritis (TIN) and Severe Cutaneous Adverse Reactions (SCARs). Lansoprazole is also associated with an increased risk of Clostridium difficile-associated diarrhea and may mask symptoms of gastric malignancy, requiring caution during initial diagnosis.

Safety notes tied to duration of use indicate an increased risk of bone fracture and hypomagnesemia (low magnesium) with long-term use (typically over one year). Official prescribing information states caution is necessary in patients with severe hepatic impairment. Furthermore, use in pediatric patients less than 1 year of age is not recommended.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents specify that overdose is generally associated with minimal clinical toxicity in adults; however, the potential for severe, though rare, effects mandates immediate medical attention. The management strategy is dictated by the fact that no specific antidote is known to counteract the drug's effects.

Documented Overdose Manifestations

Overdose presentations documented in regulatory sources primarily involve signs affecting the central nervous system (CNS) and cardiovascular system (CVS). Manifestations include somnolence (drowsiness), headache, peripheral vasodilation, and hypertension (high blood pressure). Non-specific gastrointestinal disturbances are also frequently reported.

Mandatory Emergency Action

You must seek immediate medical attention for any suspected or confirmed overdose. Contact a certified Poison Control Center or proceed directly to the nearest emergency department for comprehensive assessment and monitoring.

Official Management Protocol

Management is strictly symptomatic and supportive. Clinical specialists may consider procedures such as gastric emptying (e.g., gastric lavage) or administration of activated charcoal, if deemed appropriate. Continuous clinical monitoring of the patient’s vital signs is required due to the lack of a known antidote, ensuring patient stability.

Therapeutic Uses of Lansoprazole

Main Uses of Lansoprazole

Lansoprazole belongs to a class of medications known as proton pump inhibitors (PPIs). Its primary function is to reduce the amount of acid produced by the stomach. This reduction in gastric acid is essential for treating various conditions affecting the upper digestive tract.

Acid-Related Disorders

Lansoprazole is commonly used to manage several conditions where stomach acid causes discomfort or damage to the digestive lining:

  • Gastroesophageal Reflux Disease (GERD): This condition occurs when stomach acid frequently flows back into the tube connecting the mouth and stomach (esophagus). This backwash can irritate the lining of the esophagus, leading to symptoms such as heartburn.
  • Erosive Esophagitis: In cases of severe or chronic acid reflux, the lining of the esophagus can become inflamed or worn away. Lansoprazole helps these tissues heal by maintaining a less acidic environment.
  • Zollinger-Ellison Syndrome: This is a rare condition characterized by the formation of tumors in the pancreas or duodenum. These tumors secrete a hormone that causes the stomach to produce excessive amounts of acid.

Treatment and Prevention of Ulcers

Lansoprazole is effective in treating and preventing sores that develop on the lining of the stomach and the upper part of the small intestine (duodenum):

  • Gastric and Duodenal Ulcers: The medication promotes the healing of existing ulcers by reducing the acidic environment that prevents the tissue from recovering.
  • NSAID-Associated Ulcers: Nonsteroidal anti-inflammatory drugs (NSAIDs) can sometimes damage the stomach lining with long-term use. Lansoprazole is used both to treat ulcers caused by these medications and to prevent them in patients who must continue NSAID therapy.
  • H. pylori Eradication: When used in combination with specific antibiotics, lansoprazole helps eliminate Helicobacter pylori, a bacterium frequently responsible for the development of peptic ulcers.

Benefits of Treatment

The primary benefit of lansoprazole is the symptomatic relief it provides by controlling gastric acidity. By reducing acid production, the medication allows the esophageal and intestinal mucosa time to recover and heal. This can prevent further complications, such as strictures or significant tissue damage, and improves overall digestive comfort in individuals with chronic acid-related conditions.

Regulatory References

  1. official prescribing information from the National Institutes of Health (NIH)

Eligibility and Restrictions for Use

Who Can and Cannot Use Lansoprazole?

Eligibility for Lansoprazole use is strictly defined by regulatory authorities to ensure patient safety and effectiveness. Use is generally established for adults and for specific labeled indications in pediatric patients aged 1 to 17 years.


Absolute Contraindications

Lansoprazole must not be used by patients with a known severe hypersensitivity to the drug or its components. It is also strictly contraindicated for patients who are concurrently taking the HIV medications Rilpivirine or Nelfinavir, as co-administration significantly reduces the effectiveness of these antivirals.


Populations with Restricted or Non-Recommended Use

Population Group Regulatory Status
Infants (Under 1 year) Not recommended; efficacy is not established.
Pregnant or Breastfeeding Women Not recommended; use should be avoided as a precautionary measure.
Severe Hepatic Impairment Restricted use; a lower maximum daily dose is required.
Elderly (Geriatric) Conditional use; the maximum daily dose is generally restricted.
Phenylketonuria (PKU) Must avoid the Orally Disintegrating Tablet (ODT) formulation due to phenylalanine content.

In all cases, eligibility is determined based on the official, documented regulatory status of the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lansoprazole's interaction profile is primarily defined by its effect on gastric acidity and its involvement with hepatic enzyme systems.

Contraindicated and High-Risk Combinations

Co-administration with certain medications is restricted. Atazanavir and nelfinavir, HIV protease inhibitors, are generally not recommended due to a significant risk of reduced drug absorption, which can lead to loss of therapeutic effect. Similarly, the absorption of pH-dependent antifungal agents like ketoconazole and itraconazole may be substantially decreased.

Pharmacokinetic Interactions

Lansoprazole affects the metabolism of several drugs, chiefly through its interaction with cytochrome P450 enzymes. It may affect the levels of drugs metabolized by CYP2C19 and CYP3A4. For example, tacrolimus concentrations may be increased, requiring therapeutic drug monitoring. The effectiveness of the antiplatelet agent clopidogrel may be reduced due to the inhibition of CYP2C19, which is necessary for clopidogrel activation. Conversely, it may reduce the concentration of theophylline by inducing CYP1A2.

Administration Requirements

Due to its ability to bind to the drug in the digestive tract, sucralfate must be administered at least 30 minutes after taking lansoprazole to prevent a reduction in lansoprazole's own bioavailability. Taking lansoprazole with food is also documented to reduce its overall absorption.

Mechanism of Action

Lansoprazole's Targeted Action on the Gastric Proton Pump

Lansoprazole operates as an inactive prodrug, which selectively accumulates in the highly acidic secretory canaliculi of the gastric parietal cells. The low pH environment protonates the compound, facilitating its conversion into a reactive, active sulfenamide metabolite. This metabolite then establishes a permanent, covalent disulfide bond with accessible sulfhydryl groups on the Hydrogen-Potassium Adenosine Triphosphatase (H^+/K^+-ATPase) enzyme, commonly known as the gastric proton pump.

Suppression of the Acid Secretion Pathway

The irreversible binding event leads to the sustained inactivation of the proton pump, which suppresses the final step in the gastric acid secretion pathway. This mechanism blocks acid secretion regardless of physiological stimuli, such as histamine or gastrin. The resulting physiological consequence is a profound and prolonged reduction in the volume and acidity of gastric output, demonstrated by a significant and stable elevation of gastric pH.

Dosage and Administration Information

How to use Lansoprazole

Lansoprazole is administered primarily by the oral route using delayed-release capsules, orally disintegrating tablets (ODTs), or granules for suspension. An intravenous (IV) infusion option is also available for use when oral administration is not feasible. Oral forms must be taken before eating to optimize absorption.

Dosing and Frequency Patterns

The medication is typically taken once daily for most acute treatments and maintenance regimens. However, specific protocols, such as those for H. pylori eradication, mandate a 30 mg twice-daily schedule. Standard adult dosing ranges from 15 mg to 30 mg daily. For pathological hypersecretory conditions, the dosage may be adjusted from an initial 60 mg up to a maximum daily dose of 180 mg, which is given in divided administrations when exceeding 120 mg/day. Treatment duration varies: short courses last four to eight weeks, while maintenance therapy may be long-term.

Administration and Adjustment Rules

A key administration constraint is that the delayed-release granules must not be crushed, chewed, or ground; this is necessary to preserve the enteric coating’s integrity. For patients who cannot swallow the whole capsule, the intact granules can be mixed with specific soft foods or acidic juices, but must be swallowed immediately. Dosage adjustments are required for patients with moderate to severe hepatic impairment, where a reduced daily dose is often necessary. Dosing for pediatric patients (1–11 years) is determined by weight.

Recent Clinical Evidence

Research evidence / Overview of studies for Lansoprazole

Evidence for Healing Ulcers and Controlling H. pylori

Research has explored the use of this medicine in the context of stomach and duodenal ulcers, primarily consisting of short-term randomized controlled trials (RCTs). These studies were designed to evaluate the acute healing process by measuring the ulcer closure rate confirmed by endoscopy. Furthermore, research examined the medicine alongside antibiotics for cohorts of adults with confirmed H. pylori infection.

Studies reported measurements of patterns observed in ulcer closure and subsequent ulcer recurrence. For patients whose ulcers had already healed, intermediate-term controlled studies were used to assess the maintenance phase, observing patterns in the rate of ulcer return.

Evidence for Reflux Disease (GERD) and Erosive Esophagitis

Research has explored the use of this medicine in the context of conditions related to acid reflux, including symptomatic Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis (EE), where the evidence is based on short-term RCTs. These studies focused on outcomes related to physical discomfort and acute changes in symptoms like heartburn. Trials used endoscopy to measure the healing rate of erosive damage.

Short-term trials reported measurements of the rate of EE healing and monitored the frequency of reported symptom change. Other trials were studied for the rate of recurrence of damage over a defined time interval.

Research Gaps and Remaining Uncertainties

A key limitation in the evidence is the limited information for long-term outcomes when used for maintenance of ulcers and esophagitis, as controlled follow-up durations were often limited to 12 months. Long-term effects are not fully established; continued research explores patterns of use over many years.

Furthermore, the evidence quality varies across studies for rare conditions like Zollinger-Ellison Syndrome. Due to the rarity of these conditions, evidence is primarily derived from open-label, non-comparative studies where sample sizes were modest, and comparative evidence is limited.

Key Studies & References

  1. Lansoprazole Delayed-Release Capsules - Official Prescribing Information (DailyMed/NIH) - General Indications

Frequently Asked Questions (FAQ)

Common questions about Lansoprazole (FAQ)

Q: Is Lansoprazole the same as Omeprazole or Esomeprazole?

A: Lansoprazole belongs to the same pharmacological class of medicine known as Proton Pump Inhibitors (PPIs), similar to omeprazole and esomeprazole. While all these medicines share the primary action of reducing stomach acid, official documents describe that they differ in how each compound is processed by the body’s enzyme systems.

Q: How quickly does Lansoprazole typically start to work for acid-related symptoms?

A: According to the official product information, Lansoprazole is not intended to provide immediate relief for symptoms like heartburn. It may take between one and four days for the full therapeutic effect to become noticeable.

Q: Is Lansoprazole generally recommended for short-term use, long-term use, or both?

A: Official documentation describes both short-term courses, such as 14 days for over-the-counter use, and intermediate or long-term use for specific prescription indications. These indications often include maintenance therapy for healed erosive damage.

Q: What is 'acid rebound' and is it a potential outcome after discontinuing Lansoprazole?

A: The medicine works by creating a sustained block on the acid-producing pumps in the stomach. Regulatory guidance suggests that stopping the medicine suddenly may cause the stomach to produce a large amount of acid as the pumps recover. This change may lead to a temporary return or worsening of symptoms.

Q: What is the relationship between long-term Lansoprazole use and the risk of bone fracture?

A: Official safety documentation notes an increased risk of bone fracture of the hip, wrist, or spine in patients who use the medicine long-term, typically for one year or longer. The effect is thought to be related to the impact of chronic acid suppression on the body’s ability to absorb certain nutrients, such as calcium.

Q: What has medical research indicated about the possible association between Lansoprazole and kidney issues?

A: The development of Acute Tubulointerstitial Nephritis ( TIN), which is a serious inflammation of the kidneys, has been reported as a rare adverse reaction associated with the use of this medicine. Patients are advised to be aware of the signs of kidney problems.

Q: Is fatigue or tiredness a commonly reported side effect of Lansoprazole?

A: Yes, official safety profiles derived from clinical trials classify fatigue or tiredness as a common adverse reaction. This means it is reported in 1% to 10% of users in those studies.

Q: Is there a risk of developing joint pain or rash on sun-exposed skin while on Lansoprazole?

A: Joint pain ( arthralgia) is classified as an uncommon side effect. Regulatory documents also note the possibility of Subacute Cutaneous Lupus Erythematosus ( SCLE) and other severe cutaneous reactions, which are sometimes linked to sun exposure.

Q: Can Lansoprazole cause headaches when first starting treatment?

A: Headache is classified as a common adverse reaction. Consistent with the common nature of this effect, it can potentially occur during the initial phase of treatment as the body adjusts to the medicine.

Q: Why might Lansoprazole lead to diarrhea or constipation in some users?

A: Diarrhea and constipation are classified as common side effects. Furthermore, reducing stomach acid is documented to lower the stomach's natural defenses against harmful microorganisms. This alteration is associated with an increased risk of certain gut infections, such as Clostridium difficile-associated diarrhea.

Q: What are the signs of a potential vitamin B12 deficiency that could be associated with long-term Lansoprazole use?

A: Official warnings state that long-term use of Lansoprazole may affect the body's ability to absorb vitamin B12. Patients are advised to discuss any concerns about B12 deficiency, which may include symptoms like unusual tiredness or weakness, with a healthcare professional.

Q: Is there a known link between Lansoprazole use and low magnesium levels (hypomagnesemia)?

A: Official safety documentation notes that low magnesium levels ( hypomagnesemia) have been reported, primarily in patients using the medicine long-term. Serious symptoms can include muscle spasms, tremors, and irregular heartbeat.

Q: What information is available regarding Lansoprazole use during pregnancy?

A: The medicine is generally not recommended for use during pregnancy, and its use should be avoided as a precautionary measure. Official guidance suggests consulting a health professional for clarification regarding use during pregnancy.

Q: Is dizziness or feeling lightheaded a reported side effect of Lansoprazole?

A: Dizziness and feeling lightheaded are listed among the common side effects that have been reported in clinical experience with the use of this medicine.

Q: Can Lansoprazole affect the body's absorption of iron supplements?

A: Lansoprazole may affect the absorption of certain products, including iron supplements. By significantly reducing stomach acid, the medicine is described as potentially reducing the body's ability to effectively absorb iron.

Q: What are the documented risks of rare but severe allergic skin reactions, such as SJS or TEN, associated with Lansoprazole?

A: Official documents classify Stevens-Johnson Syndrome ( SJS) and Toxic Epidermal Necrolysis ( TEN) as very rare, but severe, cutaneous adverse reactions. Patients are advised to monitor for signs of skin reactions and seek immediate medical help if they appear.

Q: What is the maximum duration of treatment that is generally recommended for OTC Lansoprazole?

A: For over-the-counter use, the duration of treatment is limited to 14 days. Official guidance states that treatment may be repeated, but no more than one course every four months without consulting a healthcare provider.

Q: Are there different generic brands of Lansoprazole that are widely available?

A: Lansoprazole is the active ingredient (INN) for several recognized brand-name products globally, such as Prevacid and Zoton. Accordingly, generic versions of the medicine are widely available.

Q: Is there any known interaction between Lansoprazole and herbal supplements like St. John's Wort?

A: Official drug interaction information notes that the herbal supplement St. John's Wort may induce certain enzyme systems. This action could potentially reduce the concentration of Lansoprazole in the blood, decreasing its overall therapeutic effect.

Q: What are the general expectations for older adults (geriatric patients) using Lansoprazole?

A: Official guidance notes that the clearance of the medicine is decreased in older adults. For the elderly, the maximum daily dose is generally restricted, and long-term use without specific professional supervision is discouraged.

Q: What are the signs that Lansoprazole is not working to improve symptoms?

A: Signs that the medicine may not be providing the intended relief include when heartburn continues or worsens. Regulatory warnings advise seeking advice if symptoms persist after the recommended short-term treatment duration.

Q: Why is reduced stomach acid considered a risk factor for certain types of gut infections?

A: Reducing stomach acid is documented to lower the stomach's natural ability to kill harmful microorganisms that are ingested. This reduction in the protective acid barrier is associated with an increased risk of enteric infections, particularly Clostridium difficile-associated diarrhea.

Q: Does Lansoprazole interact with any common anti-seizure medications?

A: Lansoprazole is processed by certain liver enzyme systems (Cytochrome P450, primarily CYP2C19 and CYP3A4). Due to this, it has the potential to affect the blood concentrations of other medicines processed by the same enzymes, which can include some anti-seizure medications.

Q: What is the relevance of a Chromogranin A (CgA) blood test while taking Lansoprazole?

A: Official information notes that the medicine can significantly elevate blood levels of Chromogranin A ( CgA), a marker used to help detect certain tumors. Patients may be advised to temporarily discontinue the medicine before the test to avoid a false positive result.

Q: Are there any general descriptions of managing mild constipation that may occur with Lansoprazole?

A: Constipation is listed as a common side effect of the medicine. Information materials often reference general strategies for managing mild constipation, such as increasing dietary fiber and fluid intake.

How should Lansoprazole be stored and disposed of?

How to Store and Dispose of Lansoprazole

Lansoprazole must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted fluctuations up to 30 C (86 F). The product must be protected from moisture to maintain integrity.

Packaging and Child Safety

Delayed-release capsules must be stored in the original container and kept tightly closed; orally disintegrating tablets must remain in their original blister packaging. A mandatory requirement is to keep the medicine out of the reach of children.

Disposal Requirements

Unused or expired Lansoprazole must be disposed of according to local requirements. Regulatory guidance encourages the use of a medicine take-back program when one is available in the community, rather than disposal in household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lansoprazole found in:

A-Z Index: